PROK

DEFA14A - PROKIDNEY CORP. (0001850270) (Filer)

DEF 14A - PROKIDNEY CORP. (0001850270) (Filer)

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer. In this role, Mr. Madison will drive ProKidney's commercial strategy as the Company advances towards the potential commercialization of rilparencel. "Greg is a seasoned commercial biopharma executive with a proven track record of building high-performing organizations, shaping strategy, and preparing innovative therapies for market," said Bruce Culleton, M.D., CEO of ProKidney. "He brings valuable operation

S-8 - PROKIDNEY CORP. (0001850270) (Filer)

8-K - PROKIDNEY CORP. (0001850270) (Filer)

10-K - PROKIDNEY CORP. (0001850270) (Filer)

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline results in Q2 2027In a July 2025 Type B meeting, aligned with FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpointPresented positive results from the Phase 2 REGEN-007 study of rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025 followed by a peer-reviewed publication in CJASNEnded 2025 with $270.0 million in cash and cash equivalents and marketable securities, supporting operations into mid-2027 WINSTON-SALEM, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("Pro

The chronic kidney disease market growth is being driven by the rising global prevalence of diabetes, hypertension, and aging populations. Increasing awareness and earlier diagnosis are expanding the pool of patients eligible for treatment. Additionally, the launch of emerging therapies such as Zibotentan/Dapagliflozin and Baxdrostat/dapagliflozin (AstraZeneca), Vicadrostat + Empagliflozin (Boehringer Ingelheim), Lorundrostat (Mineralys Therapeutics), Rilparencel (ProKidney), DISC-0974 (Disc Medicine), Vonsetamig (Regeneron Pharmaceuticals), and others will further boost the market growth.LAS VEGAS, March 3, 2026 /PRNewswire/ -- Recently published Chronic Kidney Disease Market Insights repor

4 - PROKIDNEY CORP. (0001850270) (Issuer)

4 - PROKIDNEY CORP. (0001850270) (Issuer)

4 - PROKIDNEY CORP. (0001850270) (Issuer)

4 - PROKIDNEY CORP. (0001850270) (Issuer)

SCHEDULE 13G - PROKIDNEY CORP. (0001850270) (Subject)

8-K - PROKIDNEY CORP. (0001850270) (Filer)

8-K - PROKIDNEY CORP. (0001850270) (Filer)

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 2026Time: 8:15am PSTFormat: PresentationWebcast: Link The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website at www.prokidney.c

Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection point in late 2025, with contract development and manufacturing organizations capturing 67.5% market share as the industry transitions from boutique R&D operations to scalable bioprocessing infrastructure[1]. Gene and CAR-T therapy demand has driven CDMO partnerships to expand viral vector production and GMP-compliant facilities at unprecedented velocity, overcoming bottlenecks that previously constrained commercial access[2]. Five companies positioned at this manufacturing convergence point are attracting i

H.C. Wainwright initiated coverage of ProKidney Corp. with a rating of Buy and set a new price target of $12.00

EFFECT - PROKIDNEY CORP. (0001850270) (Filer)

4 - PROKIDNEY CORP. (0001850270) (Issuer)

144 - PROKIDNEY CORP. (0001850270) (Subject)

144 - PROKIDNEY CORP. (0001850270) (Subject)

8-K - PROKIDNEY CORP. (0001850270) (Filer)

10-Q - PROKIDNEY CORP. (0001850270) (Filer)

DEL AM - PROKIDNEY CORP. (0001850270) (Filer)